Skip to main content
Poster

Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers – Subset Analysis of Randomized Controlled Trial

Introduction: Efficacy and safety of a collagen-based wound conforming matrix (WCM), compared to standardized care (SOC), was evaluated as part of a retrospective subset analysis of a randomized, controlled, multi-center clinical study in diabetic foot ulcers (DFU). WCM consists of a highly purified homogenate of 2.6% fibrillar bovine dermal collagen that conforms to the wound surface when topically applied without trimming, suturing, or stapling. SOC consisted of daily saline-moistened gauze dressing changes.

MethodsFollowing a two-week run-in period during which patients received SOC, patients whose wounds did not reduce in area by more than 30% during run-in were randomly assigned to receive WCM (n=26) or SOC (n=15). Statistically significant acceleration of early healing rates was observed following a single application of WCM compared to SOC.

Results: At week 1, wound area decreased by 40% with a single application of WCM compared to 17% for SOC (p=0.02). At week 4, wound area decreased by 63% with a single application of WCM compared to 38% for daily SOC (p=0.02). Over a four-week period, 50% of patients receiving a single application of WCM achieved ≥75% reduction in wound area, compared to 13% for daily SOC (p=0.02).

Conclusion: WCM appeared to be safe and well-tolerated, with no adverse events related to treatment and no evidence of an immunologic reaction to bovine collagen. WCM has also been shown to activate platelets, triggering the release of platelet-derived growth factors, key mediators of wound healing. WCM’s rapid acceleration of healing is attributed to its unique native three-dimensional fibrillar collagen structure and wound conforming properties, providing a structural scaffold for migration and proliferation of repair cells, including those potentially stimulated by PDGF released from platelets activated in the wound bed by interaction with WCM.

 

Sponsor

Sponsor name
Olaregen Therapeutix Inc.